Brendan Heiden, MD, of Washington University School of Medicine, discusses data from a unique real-world cohort of nearly 1 million patients in the Veterans Health Administration; researchers evaluated whether tobacco smoking duration improves lung cancer risk prediction compared with tobacco pack-years (Abstract 8004).
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus everolimus vs elacestrant plus placebo in patients with estrogen receptor (ER)-positive HER2-negative advanced breast cancer with ESR1-mutated tumors who experienced disease progression on endocrine therapy plus CDK4/6 inhibition (Abstract TPS1154).
ClinicalTrials.gov identifier: NCT06382948
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesical recombinant bacillus Calmette-Guérin (BCG) with atezolizumab, cisplatin, and gemcitabine was feasible and safe without unexpected toxicities and demonstrates promising efficacy in patients with muscle-invasive bladder cancer (MIBC) (Abstract 4503).
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of tarlatamab-dlle, and early data for a SEZ6-targeting antibody-drug conjugate.
